BioDlink International Co (1875.HK) Stock Price
BioDlink International Co Price
Over the last 8 years BioDlink International Co grew revenue by 76.3% annually, reaching 848.36 M CNY. For BioDlink International Co, the net margin of -13.8% is up versus -353.7% a few years ago. The consensus 12-month price target for BioDlink International Co is 2.09 CNY, about 27.8% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
BioDlink International Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioDlink International Co business model & stock analysis
Frequently asked questions about BioDlink International Co
The business model of TOT BIOPHARM International Co Ltd is centered around the development, production, and commercialization of innovative biopharmaceutical products. With a focus on oncology and autoimmune diseases, TOT BIOPHARM utilizes advanced technologies and international collaborations to discover novel therapies. By integrating research, manufacturing, sales, and marketing, the company aims to deliver high-quality and cost-effective medicines to patients worldwide. As a leading biopharmaceutical company, TOT BIOPHARM is committed to improving healthcare outcomes and contributing to the advancement of medical science.
TOT BIOPHARM International Co Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of TOT BIOPHARM International Co Ltd in the market include large pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, and Roche. These companies also operate in the biopharmaceutical sector and offer a wide range of innovative drugs and therapies similar to TOT BIOPHARM.
TOT BIOPHARM International Co Ltd is a leading global biopharmaceutical company that focuses on the development and commercialization of innovative therapies. Established in (year), TOT BIOPHARM has made significant contributions to the fields of (specific areas). With a strong commitment to research and development, the company has successfully launched several breakthrough drugs, including (drug names). TOT BIOPHARM's exemplary track record of delivering effective treatments has earned them a reputable position in the pharmaceutical industry. With a dedicated team of experts and state-of-the-art facilities, TOT BIOPHARM continues to strive for excellence in improving patient outcomes and revolutionizing healthcare worldwide.
TOT BIOPHARM International Co Ltd has achieved several significant milestones in its journey. The company has demonstrated its commitment to innovation and research in the biopharmaceutical industry. One of the noteworthy accomplishments includes the successful development and commercialization of groundbreaking medicines that have positively impacted patient lives globally. TOT BIOPHARM International Co Ltd has also established strategic partnerships with leading healthcare organizations, enabling the company to expand its reach and further contribute to the advancement of healthcare worldwide. Additionally, the company has achieved remarkable growth and recognition, solidifying its position as a prominent player in the biopharmaceutical market. TOT BIOPHARM International Co Ltd continues to strive towards excellence in delivering innovative solutions for improving global healthcare.
TOT BIOPHARM International Co Ltd is primarily present in China, as it is a Chinese biopharmaceutical company. The company is focused on the research, development, and commercialization of innovative therapeutics for oncology and other diseases. With its headquarters in Suzhou, TOT BIOPHARM operates across various provinces in China, including Shanghai, Beijing, Guangdong, and Jiangsu. As a leading player in the Chinese biopharmaceutical industry, TOT BIOPHARM aims to expand its presence both domestically and internationally, contributing to the advancement of healthcare and the treatment options available to patients worldwide.
TOT BIOPHARM International Co Ltd is a renowned pharmaceutical company that is committed to delivering innovative treatments and improving global health. The company values integrity, excellence, and collaboration in all aspects of its operations. TOT BIOPHARM upholds a corporate philosophy focused on customer satisfaction, quality assurance, and social responsibility. By adopting cutting-edge technology and stringent quality control measures, the company consistently produces high-quality pharmaceutical products. TOT BIOPHARM's dedication to research and development demonstrates its persistent drive to provide breakthrough solutions in the healthcare industry. With a strong emphasis on patient well-being and ethical conduct, TOT BIOPHARM International Co Ltd is a trusted leader in the pharmaceutical sector.
Analysts currently set an average price target of 2.09 CNY for the BioDlink International Co stock (median: 2.09 CNY), implying -37.9 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the BioDlink International Co stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioDlink International Co to generate revenue of 597.11 M CNY and earnings per share of 0.01 CNY.
Converted at the current exchange rate, the BioDlink International Co share trades at 0.39 EUR (2.89 CNY).
TOT BIOPHARM International Co Ltd is a biopharmaceutical company that was founded in 2000 and is headquartered in Beijing, China. The company is engaged in the research, development, manufacturing, and marketing of innovative drugs for the treatment of cancer and other serious diseases. The business model of TOT BIOPHARM is based on three divisions: research and development, manufacturing, and marketing of drugs. In the research and development department, scientists work to develop new drugs and improve existing ones. The company has a strong research infrastructure that allows it to implement the latest discoveries in cancer research. Drug manufacturing is another important division. TOT BIOPHARM has a 40,000-square-meter production facility in Beijing where state-of-the-art technologies are used to produce high-quality and safe drugs. The company has comprehensive quality assurance and control systems to ensure the purity, efficacy, and safety of the drugs. The marketing of drugs is the third pillar of TOT BIOPHARM's business model. The company has a wide distribution network in China and is working to expand its reach to global markets. It has formed partnerships with leading pharmaceutical companies worldwide to market its drugs internationally. TOT BIOPHARM offers a wide range of drugs for the treatment of cancer and other serious diseases. The key products include: 1. Yiviva: An innovative drug for the treatment of breast cancer, based on the blocking effect of progesterone receptors. 2. Disitamab vedotin: An antibody-drug conjugate for the treatment of cancer, currently in phase III clinical trials. 3. TAA401: An immunotherapy developed by TOT BIOPHARM for the treatment of advanced stage liver cancer. 4. TP-0903: A tyrosine kinase inhibitor specifically designed for the treatment of central nervous system tumors. 5. ABBV-157: A drug developed in collaboration with AbbVie Inc., currently in phase III clinical trial for the treatment of pancreatic cancer. Overall, TOT BIOPHARM focuses on the research, development, and marketing of innovative drugs for the treatment of cancer and other serious diseases. Through a strong research infrastructure, state-of-the-art production facilities, and a wide distribution network, the company has been able to expand its reach to global markets while maintaining a focus on the quality and safety of its drugs.
The expected revenue of BioDlink International Co is 597.11 M CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioDlink International Co is 7.65 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioDlink International Co is currently 274.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioDlink International Co stock.
The price-to-sales ratio (P/S) of BioDlink International Co is currently 3.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioDlink International Co stock.
The Eulerpool Quality Score for BioDlink International Co is 4/10.
The ISIN of BioDlink International Co is HK0000545266. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of BioDlink International Co is 1875.HK. The ticker symbol is used to trade BioDlink International Co shares on the stock exchange.
BioDlink International Co stock
BioDlink International Co Peer Group
BioDlink International Co FIGI
All fundamentals and in-depth analysis of BioDlink International Co
Our stock analysis for BioDlink International Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioDlink International Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.